Market Access & Reimbursement
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Access
New report finds increase in use of deductibles and coinsurance charging members list prices.
The pan-Canadian Pharmaceutical Alliance has negotiated product listing agreements with three hepatitis C drug makers in one of its first major negotiations with multiple manufacturers. The pCPA may want to negotiate more deals with several companies at once, particularly those with drugs in crowded markets.
Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.
India’s Health Minister says a new national health care roadmap marks a “huge milestone” towards fixing the country’s failing medical delivery system. But critics say while the scheme is a step in the right direction, it largely recycles old, unmet goals from years ago and caution that implementation will be key.
Medicaid block grant funding mechanism, which could allow states to bypass coverage requirements in the Medicaid drug rebate program, surfaces in House American Health Care Act.
The multi-faceted UK life sciences industry has been told to develop more connective tissue and encourage a more activist government industrial strategy to help it thrive after the country departs the European Union.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.